Willis Maddrey
Hepatology · Dallas, TXNPI 1528037009
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $284,296 of the $288,939 with a category attached, or 98.4%. 14 manufacturers reported payments, led by Actelion Pharmaceuticals, Ltd at 36.3% of the total. Reporting peaked in 2019 at $160,462 and has fallen 88.4% since, to $18,688 in 2024. Among hepatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $2675.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals, Ltd$105K
- Pfizer$56K
- Intercept Pharmaceuticals, Inc.$49K
- Merck$13K
- Sarepta Therapeutics, Inc.$11K
- Janssen Research & Development, LLC$11K
- plus $45K from 8 others
Across 8 payments — averaging $2628.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$21K
What the payments were for
- Consulting fees$284,29698%
- Speaking & faculty fees$2,2751%
- Travel & lodging$2,0211%
- Food & beverage$3470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals, Ltd | 22 | $104,828 |
| Pfizer | 23 | $55,738 |
| Intercept Pharmaceuticals, Inc. | 22 | $48,526 |
| Merck | 6 | $12,588 |
| Sarepta Therapeutics, Inc. | 6 | $10,958 |
| Janssen Research & Development, LLC | 6 | $10,831 |
| GSK | 6 | $10,475 |
| Bristol Myers Squibb | 5 | $10,096 |
| Astellas Pharma Global Development | 3 | $6,500 |
| Coherus Oncology, Inc. | 1 | $6,013 |
| Akcea Therapeutics, Inc. | 3 | $4,000 |
| Daiichi Sankyo Inc. | 1 | $3,625 |
| CSL Behring | 3 | $3,261 |
| Lexicon Pharmaceuticals, Inc. | 1 | $1,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$99,906
- OCALIVA$36,938
- XELJANZ$23,400
- Exondys 51$10,958
- ZEPOSIA$9,263
- Veozah$6,500
- MK-5172$5,163
- Xermelo$1,500
- SCH-018908 - RIBAVIRIN$1,250
- Ozanimod$833
How this compares
$288,939 in reported general payments places this provider in the 95th percentile of 22 hepatology providers in Texas.
Other hepatology in Dallas
- Amit SingalDallas$534K
- William LeeDallas$101K
- Marlyn MayoDallas$67K
- Robert RahimiDallas$18K
- Gary DavisDallas$9K
- Maria Lepe-SuasteguiDallas$4K
- Ussama GhummanDallas$1K
- Sarah LieberDallas$285
- Joseph GalatiHouston$211K
- Hesham ElgouhariDenison$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.